Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
This bill amends the Controlled Substances Act to add synthetic 7-hydroxymitragynine (7-OH) and its synthetic equivalents to Schedule I.
The text explicitly excludes 7-hydroxymitragynine that is naturally contained in the kratom plant (Mitragyna speciosa).
Content is narrow and administratively feasible, but subject-matter controversy and potential stakeholder opposition reduce prospects, especially in Senate.
Relative to its intended legislative type, this bill is a concise statutory amendment that directly places 7-hydroxymitragynine and its synthetic equivalents into Schedule I while excluding naturally occurring 7-hydroxymitragynine in Mitragyna speciosa. It uses the standard legislative mechanism for scheduling but omits technical definitions, implementation timing, fiscal considerations, and provisions addressing common edge cases and oversight.
Progressives stress public health and anti-criminalization safeguards.
Progressives stress public health and anti-criminalization safeguards.
Likely to view the bill as a targeted public-health measure to restrict a potent synthetic opioid while preserving natural kratom.
Supportive of efforts to reduce harms from synthetic opioids, but cautious about criminalization and enforcement disparities.
Will likely see the bill as a narrowly targeted regulatory step addressing a dangerous synthetic opioid while avoiding a ban on the natural plant.
Appreciates clarity but wants careful implementation details on definitions and research exemptions.
Mixed reaction: supportive of restricting dangerous synthetic opioids but wary of expanding Schedule I and federal reach.
The explicit exclusion for natural kratom reduces business and liberty concerns, but caution remains about enforcement scope and impacts on research or commerce.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and administratively feasible, but subject-matter controversy and potential stakeholder opposition reduce prospects, especially in Senate.
The bill has not accumulated any surfaced votes yet.
Progressives stress public health and anti-criminalization safeguards.
Content is narrow and administratively feasible, but subject-matter controversy and potential stakeholder opposition reduce prospects, espe…
Relative to its intended legislative type, this bill is a concise statutory amendment that directly places 7-hydroxymitragynine and its synthetic equivalents into Schedule I while excluding naturally occurring 7-hydroxy…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.